MerTK is capable of bypassing the blocked cascades, thereby rescuing cells from the anti-oncogenic treatment, and in consequence, dual therapy with either EGF-R or NFκB plus MerTK inhibitors strongly reduced viability and tumor growth [74,75]. This evidence concerns the gene MERTK and neoplasm.